Intensity Therapeutics' Data on Lead Asset, INT230-6, Accept

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Washington , United States , Westport , Ottawa , Ontario , Canada , Edna Kaplan , Nilofer Azad , Lilianl Siu , Matthew Ingham , Syed Mahmood , Christianf Meyer , Anthonyj Olszanski , Matthewa Ingham , Gilesf Whalen , Michael Miller , Jacob Thomas , Bristol Myers Squibb , Anthony El Khoueiry , Diana Hanna , Ianb Walters , Merck Sharpe Dohme , Lewish Bender , Albirunir Razak , Development Agreement , Ontario Institute Of Cancer Research , Ottawa Hospital Research Institute , National Cancer Institute , Society For Immunotherapy Of Cancer , Bristol Myers Squibb Company , Columbia University Medical Center , Waltere Washington Convention Center , Intensity Therapeutics Inc , Rx Communications Group , Vaccine Branch , Connective Tissue Oncology Society Annual Meeting , York Presbyterian Hospital Columbia University Medical Center , Division Of Hematology , Intensity Therapeutics , Annual Meeting , Assistant Professor , New York Presbyterian , Adult Subjects , Metastatic Sarcomas , Immune Response Data , Locally Advanced , Metastatic Solid , Clinical Trials , Friday November , Convention Center , Favorable Safety Profile , Early Signs , Advanced Soft Tissue Sarcoma , Merck Sharpe , Ontario Institute , Cancer Research , Cooperative Research , Intensity Therapeutic , Relations Contact , Nc ,